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Alternative for pre-anesthetic sedation and for surgical 
procedures in children: use of intranasal midazolam
Agitated and uncooperative children are frequently a challenge 
for safe anesthetic induction or urgent surgical procedures 
in emergency departments. Promoting anxiolysis and light 
sedation facilitates the performance of such procedures, 
reducing the adverse effects and increasing parents’ and 
health care team’s satisfaction. In a recently published study 
by Kawanda et al.,1 intranasal midazolam was used at a dose 
of 0.5 mg/kg in 52 children submitted to 85 clinical and surgical 
procedures; the control group consisted of 28 children who 
were submitted to 55 procedures with no pre-anesthetic 
medication. As clinical outcomes, patients’ behavior and 
sedation level were evaluated, along with ease of performing 
surgical procedure, which has been evaluated by the surgeon. 
For both clinical outcomes, there was a statistically significant 
difference among children’s behavior and degree of agitation, 
as well as ease of finishing the procedure in previously 
medicated children, when compared to the control group.
Sedation for pediatric surgical procedures by non-invasive 
pathways can favor their performance, considering that 
there is no need for venous access, which is safe for light and 
moderate degrees of sedation. Midazolam is a water-soluble 
benzodiazepinic drug, effective for reaching such degrees 
of sedation in doses that vary from 0.3 to 0.5 mg/kg;2 the 
intranasal pathway was shown to be effective in obtaining 
drug levels in the subarachnoid space similar to those found 
after intravenous administration, due to the presence of 
a rich vascular plexus that freely communicates with the 
aforementioned space through the olfactory nerve.3 Intranasal 
midazolam has already been studied in the context of sutures, 
peripherical venipunctures, and echocardiograms, with no 
occurrence of adverse respiratory and cardiovascular events, 
and with a high success rate in surgical procedures.4,5 It has 
been recently studied as a pre-anesthetic medication;5 data 
similar to those from the study presented demonstrate the 
tendency for obtaining good results by administering the drug, 
which has been gaining prominence for sedation in surgical 
procedures with children.
Some problems related to the administration of midazolam 
are well-known. The medication is kept in benzyl-alcohol, 
which guarantees a PH level close to three, which is 
uncomfortable and causes nasal burning. In order to mitigate 
such discomfort, two measures can be taken: administration 
of the drug with an atomizer specific for the nasal mucosa, 
which disperses the liquid into droplets, ensuring absorption 
only by the nasal mucosa, and reducing the volume of the 
assimilated drug; and the concomitant administration of 
lidocaine, as described by Chiaretti et al.,3 which besides 
mitigating the discomfort, also appears not to interfere with 
the drug action. Another relevant aspect is the drug dilution. 
Midazolam administered by nasal pathway is the same 
parenteral solution of 5 mg/mL. Such a dilution requires high 
volumes of drug depending on the child’s weight; the higher 
the volume administered by nasal pathway, the higher the 
percentage assimilated, with probable reduction in the effect. 
It should be emphasized that midazolam may also be used 
as a mouth spray. The absorption by oral mucosa seems to 
be as effective as by nasal pathway, with similar results in 
improving pre-surgical anxyolisis.4 More recent options 
are being studied for intranasal administration, such as 
dexmedetomidine,6 a potent alpha-2 adrenergic agonist, 
which has the benefit of inducing a sleep state similar to the 
physiological state, and presenting few adverse events when 
compared to the parenteral pathway. 
The higher success rates for sedation using this 
agent, associated with the lower doses needed for nasal 
administration by dilution and the profile of few adverse 
events make it an interesting option for surgical sedation for , 
although it is still in an initial stage of studies on the pediatric 
population.
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